Cat. #161769
OV-1369(R2) cell line
Cat. #: 161769
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de Luniversité de Montréal
Primary Citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: OV-1369(R2) cell line
- Alternate name: OV-1369(R2)
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
- Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 7; Carboplatin/Taxol
- Morphology: Expresssion of tumor suppressor p53 present. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: aggregate
- Growth properties: Adherent
- Crispr: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell lines spontaneously derived from ascites at specific time points at diagnosis and relapse. Post-treatment for breast cancer 2 years before
- Production details: Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement.
- Additional notes: Patient was diagnosed with breast cancer 18 months before ovarian cancer diagnosis. After surgical resection for breast cancer and 14 months before ovarian cancer diagnosis, patient had docetaxel treatment. Patient was also entrolled in a clinical trial obtaining doxorubicin, docetaxel with or without cyclophosphamide and received radiotherapy 12 months before ovarian cancer diagnosis. After ovarian cancer diagnosis, patient received paclitaxel and carboplatin for 5 months and was initially r...
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
- Cultured in antibiotics: Amphotericin B and Gentamicin
References
- Tomas et al. 2023. J Ovarian Res. 11
- 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11
- 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11
- 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4
- 12:856424. PMID: 35600398
